About Aptorum Group
Aptorum Group is a company based in London (United Kingdom) founded in 2017 by Ian Huen. The company has 1 employees as of December 31, 2024. Aptorum Group operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
- Headquarter London, United Kingdom
- Employees 1 as on 31 Dec, 2024
- Founders Ian Huen
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aptorum Group Limited
-
Annual Revenue
Not available
-
Net Profit
-$4.27 M (USD)-51.09as on Dec 31, 2024
-
EBITDA
-$3.54 M (USD)62.32as on Dec 31, 2024
-
Latest Funding Round
$3 M (USD), Post-IPO
Dec 09, 2022
- Investors
-
Employee Count
1
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aptorum Group
Aptorum Group is a publicly listed company on the NASDAQ with ticker symbol APM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Aptorum Group
Unlock access to complete
Funding Insights of Aptorum Group
Investors in Aptorum Group
Aptorum Group has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Aenco.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Blockchain-based financial solutions for healthtech are provided.
|
Locked | Locked | Locked |
Investor details for Aptorum Group
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aptorum Group
Investment portfolio details for Aptorum Group
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aptorum Group
Detailed financials for Aptorum Group
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aptorum Group Comparisons
Peer comparison for Aptorum Group
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aptorum Group
Aptorum Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
Detailed competitors of Aptorum Group
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aptorum Group
Complete news archive for Aptorum Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aptorum Group
Aptorum Group was founded in 2017 and raised its 1st funding round 5 years after it was founded.
Aptorum Group is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Ian Huen is the current CEO of Aptorum Group. They have also founded this company.
As of Dec 31, 2024, the latest employee count at Aptorum Group is 1.
Aptorum Group was founded in 2017 and is headquartered in London, United Kingdom. Operations focus on the biotechnology sector, where small molecular therapeutics are developed to address various disorders. The pipeline includes drug candidates such as SACT-1 for neuroblastoma, ALS-4 for staphylococcus infections, ALS-1 for influenza, ALS-2 for bacterial infections, NLS-1 for endometriosis, and additional compounds. Leadership is provided by founder and CEO Ian Huen.
Aptorum Group's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Yes, Aptorum Group is publicly traded on NASDAQ under the ticker symbol APM.
Aptorum Group has 1 investor. Key investors include Aenco.
The ticker symbol of Aptorum Group is APM on NASDAQ.